What are the latest clinical trials for Non-Small Cell Lung Cancer in 2026

Latest Clinical Trials for Non-Small Cell Lung Cancer in 2026

I appreciate your question about current clinical trials. However, I need to be transparent about an important limitation: my knowledge was last updated in early 2025, so I don't have access to newly launched trials specifically from 2026.

That said, I can share what the most recent NCCN Guidelines (Version 8.2025) tell us about the treatment directions and approaches that are actively being studied and refined for NSCLC, which will inform 2026 trials.

Active Treatment Areas Based on Latest Guidelines

According to the NCCN Guidelines for Non-Small Cell Lung Cancer (Version 8.2025), here are the major research and treatment focus areas:

1. Targeted Therapy for Specific Mutations

The guidelines highlight ongoing development in:

• EGFR mutations: Newer combinations like amivantamab plus lazertinib for previously untreated patients
• ALK rearrangements: Advanced ALK inhibitors including lorlatinib and newer agents
• ROS1 fusions: Recent approvals include repotrectinib and taletrectinib (newly approved in 2024-2025)
• BRAF V600E mutations: Dabrafenib plus trametinib combinations
• MET exon 14 alterations: Capmatinib and tepotinib
• KRAS G12C mutations: Sotorasib and adagrasib
• HER2 mutations: Trastuzumab deruxtecan and newer HER2-targeted agents

2. Immunotherapy Combinations

Active research areas include:

• PD-L1 checkpoint inhibitors combined with chemotherapy
• Dual immunotherapy: Nivolumab plus ipilimumab combinations
• Immunotherapy after chemoradiation: Durvalumab consolidation (proven effective in stage III disease)

3. Early-Stage and Resectable Disease

According to NCCN Guidelines, emerging trials focus on:

• Neoadjuvant therapy (treatment before surgery) with targeted agents and immunotherapy
• Adjuvant osimertinib for EGFR-mutated resected cancers
• Adjuvant immunotherapy after surgery and chemotherapy

4. Stage III Unresectable Disease

The PACIFIC trial demonstrated that durvalumab after chemoradiation improves survival. Current research is exploring:

• Enhanced chemoradiation regimens
• Combination immunotherapy approaches
• Integration of targeted therapy with radiation

How to Find Current 2026 Trials

For the most up-to-date information on active clinical trials launching in 2026, I recommend:

1. ClinicalTrials.gov (www.clinicaltrials.gov)

   • Search: "Non-Small Cell Lung Cancer" + "2026"
   • Filter by recruitment status and location

2. NCCN Patient Resources

   • Visit NCCN.org for their patient guides on NSCLC, which include trial information

3. Cancer Centers

   • Major NCI-designated cancer centers (like Memorial Sloan Kettering, MD Anderson, Mayo Clinic) maintain current trial listings

4. Advocacy Organizations

   • Lung Cancer Alliance
   • American Lung Association
   • These often have trial-matching services

5. Your Oncology Team

   • Your doctor can identify trials matching your specific diagnosis, stage, and biomarker status

Key Questions to Ask About Any Trial

When evaluating a 2026 trial, ask your healthcare team:

1. How does this trial's approach differ from current standard treatment?
2. What is the phase of the trial? (Phase I = safety; Phase II = effectiveness; Phase III = comparison to standard care)
3. What are the inclusion/exclusion criteria, and do I qualify?
4. What are the potential benefits and risks specific to me?
5. How often will I need to visit the treatment center?
6. Will the trial be free, or will I have costs?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial participation.